Interferons have been a major treatment for myeloproliferative neoplasms (MPNs) for decades, but emerging therapies are expanding the treatment armamentarium, explained Raajit Rampal, MD, PhD, of ...

An expert discusses how rilzabrutinib’s oral administration and broad tolerability make it a practical treatment option while ...

Myeloproliferative disorders include several different conditions that are characterized by excess production of blood cells ...

A patient advocate discusses the difficulties of finding and participating in clinical trials for MPNs, and the impact on research and treatment development. Despite the need for patients with ...

This particular designation may expedite the process of approving Xpovio for the treatment of patients with myelofibrosis to address an unmet medical need. The Food and Drug Administration (FDA) ...